CRON
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Cronos Group Inc. publishes a filing, an earnings call transcript or a press release.
Get CRON alertsAnna Shlimak is recorded as CFO at Cronos Group Inc. (CRON). The newest filing on record that lists Anna Shlimak as CFO at Cronos Group Inc. (CRON) is dated April 24, 2026. Cronos Group Inc. reported in an 8-K filed March 19, 2025 that Anna Shlimak was appointed Chief Financial Officer, effective March 19, 2025. The proxy statement of Cronos Group Inc. reports total compensation of $1,223,280 for Anna Shlimak in fiscal 2025, including a base salary of $356,024. Disclosed compensation is on record for 6 fiscal years. Anna Shlimak has spoken on 7 earnings calls across 1 company, most recently for Cronos Group Inc. on August 6, 2026. Cronos Group Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Cronos Group Inc. includes Michael Gorenstein (CEO, Chairman and Board Member), Michael Gorenstein Chairman (CEO), Ran Gorelik (Chairman) and 7 others.
“Effective as of March 19, 2025 (the “Effective Date”), Cronos Group Inc. (the “Company”) has appointed Anna Shlimak, the Company’s Chief Strategy Officer, as the Company’s Chief Financial Officer.”
“I will now review our second quarter 2026 results. The company reported consolidated net revenue of $53 million, a 58% increase year over year.”
“I'll now review our fourth quarter 2025 results. The company reported consolidated net revenue of $44.5 million, a 47% increase year-over-year. The net revenue increase was driven by higher cannabis flower sales in Israel, Canada, and other countries, and higher cannabis extract sales in the Canadian market.”
“I will now review our third quarter 2025 results. The company reported consolidated net revenue of $36.3 million, a 6% increase year over year.”
“I will now review our second quarter 2025 results. The company reported consolidated net revenue of $33.5 million, a 21% increase from the prior year period. Net revenue for Kronos, excluding Groco, was $31.2 million, representing a 13% growth year-over-year.”
“I will now review our first quarter 2025 results, which include the consolidation of GrowCo’s financials. The company reported consolidated net revenue of $32.3 million, a 28% increase from the prior year period, with constant currency net revenue growth higher at 33% year-over-year.”
Start not stated–present
Last confirmed April 24, 2026
Proxy statement
Start not stated–2024-04-26
Last confirmed by a filing; no departure on record
CRON
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cronos Group Inc. (CRON) | CFO | $356,024 | $1,223,280 |
| 2024 | Cronos Group Inc. (CRON) | SVP, Corporate Affairs and Strategy; CFO | $279,231 | $836,509 |
| 2023 | Cronos Group Inc. (CRON) | SVP, Corporate Affairs and Strategy; CFO | $270,000 | $739,228 |
| 2022 | Cronos Group Inc. (CRON) | SVP, Corporate Affairs and Strategy; CFO | $270,000 | $800,505 |
| 2021 | Cronos Group Inc. (CRON) | SVP, Corporate Affairs and Strategy | $230,000 | $652,027 |
| 2020 | Cronos Group Inc. (CRON) | SVP, Corporate Affairs and Strategy | $191,077 | $1,083,303 |